



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Rundfeldt, et al.

Serial No.

10/611,649

Filed

July 1, 2003

For

TOPICAL TREATMENT OF SKIN DISEASES

Art Unit

To be assigned

Examiner

To be assigned

December **3**, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA. 22313-1450

Ď

I hereby certify that this correspondence is being deposited with the United States Postal Service by first class mail in an envelope addressed to Commissioner for Patents, P. O. Box 1450, Alexandria, VA. 22313-1450 on the date shown below:

Eileen Sheffield

Signatur

Date

## INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

These references were cited in an International Search Report (copy enclosed).

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any

patent, publication or other information referred to therein is "prior art" for this invention unless

specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement

shall not be construed to mean that a search has been made or that no other material information

as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is

in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed

references.

The Commissioner is hereby authorized to charge any deficiency in the fees filed,

asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in

this application by this firm) to our Deposit Account No. 50-0624, under Order No. NY-HUBR-

1221-US. A duplicate copy of this paper is enclosed.

Respectfully submitted

FULBRIGHT & JAWORSKI L.L.P.

James R. Crawford

Reg. No. 39,155

666 Fifth Avenue New York, New York 10103 (212) 318-3148



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031 U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paper Approximation Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
000				Application Number	10/611,649	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	July 1, 2003	
				First Named Inventor	Rundfeldt, et al.l.	
				Art Unit		
(use as many sheets as necessary)				Examiner Name		
Sheet	1	of		Attorney Docket Number	HUBR-1221 (10307755)	

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Patentee or Applicant	Pages, Columns, Lines, Where Relevant
		Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	of Cited Document	Passages or Relevant Figures Appear
	AA	US-6,251,923 B1	6/26/01	Polymeropoulos	

		FOREI	GN PATENT D	OCUMENTS		
Evernines	Cito	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No. <sup>1</sup>	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	1	Applicant of Cited Document	Passages or Relevant Figures Appear	T <sup>6</sup>
			·			
	,, ,, ,, ,,					

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		Effects of the Phosphodiesterase 4 inhibitorsDermatitis, Baumer, et al. European Journal of Pharmacology, 6/20/02, Vol. 446, No. 1-3				
		Studies with AWD 12281 in the Skin of Sensitized Mice, Ehinger, et al., Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, vol. 363, no. 4				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
CAUTILION 1		
Signature	Considered	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.